Bone Health in Children with Primary Hyperoxaluria Type 1 Following Liver and Kidney Transplantation

Overview

Journal Front Pediatr

Specialty Pediatrics

Date 2024 Mar 8

PMID 38455394

Authors

Rainer Buscher

Lars Pape

Anja K Buscher

Affiliations

Soon will be listed here.

Abstract

Background: Primary hyperoxaluria type 1 is characterized by hepatic oxalate overproduction, leading to nephrocalcinosis, kidney stones, kidney failure and systemic oxalosis, including oxalate osteopathy. Combined liver-kidney transplantation (CLKT) and kidney after liver transplantation (KALT) were established therapeutic options to stop the devastating consequences of oxalate bone disease.

Methods: We describe a retrospective cohort of 10 children with PH1who were referred to our hospital from different countries for combined transplantation. Demographic and clinical data were collected and symptoms of bone disease, conventional radiological examinations, plasma oxalate levels and other determinants of calcium-phosphate metabolism were compared pre and post transplantation.

Results: Ten patients (7 male, median age 5.8 years, median follow-up time 8.1 years) were included in this study. Seven patients were diagnosed with infantile oxalosis and 9 patients received an intensified dialysis regime prior to transplantation. In one patient the transplanted kidney never achieved primary function and the boy remained on HD. All other patients remained without graft failure and retained stable kidney and liver function. Prior to transplantation, seven patients suffered from severe skeletal pain and three children presented with 1-3 series of pathological fractures. Pathological fractures did no longer occur in children who underwent successful CLKT or KALT. Plasma oxalate levels dropped within 6 months following Tx. Determinants of calcium-phosphorus metabolism did not differ significantly in comparison to other HD children. Seven of ten children showed a restricted growth at the time of transplantation and presented a moderate catch-up-growth at the time of last follow-up.

Conclusions: Patients with PH1 suffer from severe consequences of a disturbed bone metabolism. However, bone health and growth can partially improve following CLKT/KALT.

Citing Articles

Mutation Characteristics of Primary Hyperoxaluria in the Chinese Population and Current International Diagnosis and Treatment Status.

Zhu X, Cheung W, Zhang A, Ding G Kidney Dis (Basel). 2024; 10(4):313-326.

PMID: 39131880 PMC: 11309763. DOI: 10.1159/000539516.

References

Toussaint C, Vienne A, De Pauw L, Gelin M, Janssen F, Hall M . Combined liver-kidney transplantation in primary hyperoxaluria type 1. Bone histopathology and oxalate body content. Transplantation. 1995; 59(12):1700-4. DOI: 10.1097/00007890-199506270-00010. View

Harambat J, van Stralen K, Espinosa L, Groothoff J, Hulton S, Cerkauskiene R . Characteristics and outcomes of children with primary oxalosis requiring renal replacement therapy. Clin J Am Soc Nephrol. 2012; 7(3):458-65. PMC: 3302673. DOI: 10.2215/CJN.07430711. View

Soliman N, Nabhan M, Abdelrahman S, Abdelaziz H, Helmy R, Ghanim K . Clinical spectrum of primary hyperoxaluria type 1: Experience of a tertiary center. Nephrol Ther. 2017; 13(3):176-182. PMC: 5921832. DOI: 10.1016/j.nephro.2016.08.002. View

Birtel J, Herrmann P, Garrelfs S, Dulz S, Atiskova Y, Diederen R . The Ocular Phenotype in Primary Hyperoxaluria Type 1. Am J Ophthalmol. 2019; 206:184-191. DOI: 10.1016/j.ajo.2019.04.036. View

Hoppe B . An update on primary hyperoxaluria. Nat Rev Nephrol. 2012; 8(8):467-75. DOI: 10.1038/nrneph.2012.113. View

Hage S, Ghanem I, Baradhi A, Mourani C, Mallat S, Dagher F . Skeletal features of primary hyperoxaluria type 1, revisited. J Child Orthop. 2009; 2(3):205-10. PMC: 2656805. DOI: 10.1007/s11832-008-0082-4. View

Illies F, Bonzel K, Wingen A, Latta K, Hoyer P . Clearance and removal of oxalate in children on intensified dialysis for primary hyperoxaluria type 1. Kidney Int. 2006; 70(9):1642-8. DOI: 10.1038/sj.ki.5001806. View

Ben-Shalom E, Cytter-Kuint R, Rinat C, Becker-Cohen R, Tzvi-Behr S, Goichberg J . Long-term complications of systemic oxalosis in children-a retrospective single-center cohort study. Pediatr Nephrol. 2021; 36(10):3123-3132. DOI: 10.1007/s00467-021-05002-1. View

Bacchetta J, Boivin G, Cochat P . Bone impairment in primary hyperoxaluria: a review. Pediatr Nephrol. 2015; 31(1):1-6. DOI: 10.1007/s00467-015-3048-z. View

10.

Murad S, Eisenberg Y . ENDOCRINE MANIFESTATIONS OF PRIMARY HYPEROXALURIA. Endocr Pract. 2017; 23(12):1414-1424. DOI: 10.4158/EP-2017-0029. View

11.

Hoppe B, Kemper M, Bokenkamp A, Portale A, Cohn R, Langman C . Plasma calcium oxalate supersaturation in children with primary hyperoxaluria and end-stage renal failure. Kidney Int. 1999; 56(1):268-74. DOI: 10.1046/j.1523-1755.1999.00546.x. View

12.

Buscher R, Buscher A, Cetiner M, Treckmann J, Paul A, Vester U . Combined liver and kidney transplantation and kidney after liver transplantation in children: Indication, postoperative outcome, and long-term results. Pediatr Transplant. 2015; 19(8):858-65. DOI: 10.1111/petr.12595. View

13.

Deesker L, Garrelfs S, Mandrile G, Oosterveld M, Cochat P, Deschenes G . Improved Outcome of Infantile Oxalosis Over Time in Europe: Data From the OxalEurope Registry. Kidney Int Rep. 2022; 7(7):1608-1618. PMC: 9263236. DOI: 10.1016/j.ekir.2022.04.012. View

14.

Ben-Shalom E, Frishberg Y . Primary hyperoxalurias: diagnosis and treatment. Pediatr Nephrol. 2014; 30(10):1781-91. DOI: 10.1007/s00467-014-3030-1. View

15.

Bacchetta J, Fargue S, Boutroy S, Basmaison O, Vilayphiou N, Plotton I . Bone metabolism in oxalosis: a single-center study using new imaging techniques and biomarkers. Pediatr Nephrol. 2010; 25(6):1081-9. DOI: 10.1007/s00467-010-1453-x. View

16.

Nissel R, Latta K, Gagnadoux M, Kelly D, Hulton S, Kemper M . Body growth after combined liver-kidney transplantation in children with primary hyperoxaluria type 1. Transplantation. 2006; 82(1):48-54. DOI: 10.1097/01.tp.0000225831.35143.06. View

17.

Behnke B, Kemper M, Kruse H, Muller-Wiefel D . Bone mineral density in children with primary hyperoxaluria type I. Nephrol Dial Transplant. 2001; 16(11):2236-9. DOI: 10.1093/ndt/16.11.2236. View

18.

Garrelfs S, Frishberg Y, Hulton S, Koren M, ORiordan W, Cochat P . Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1. N Engl J Med. 2021; 384(13):1216-1226. DOI: 10.1056/NEJMoa2021712. View